Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
RESEARCH TOOLSreports
Holding DWTX?
Track your performance easily
DWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.50 - $26.00
Previous Close$4.45
Volume13.37K
Average Volume (3M)92.32K
Market Cap
$5.93M
Enterprise Value$2.91M
Total Cash (Recent Filing)$3.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.95
Next Earnings
Nov 11, 2024EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.87
Shares Outstanding1,332,268
10 Day Avg. Volume51,202
30 Day Avg. Volume92,321
Standard Deviation0.36
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.89
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$15.00Price Target Upside237.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Dogwood Therapeutics News
Bulls Say, Bears Say
Bulls Say
Funding And Financial SupportCLKS provides significant funding with a $19.5M loan, which supports the development of assets and potentially additional financing.
Market Opportunity And SafetyThe U.S. market for Long COVID alone could reach several million patients and the lack of any specifically approved therapies, success in this study could be a major catalyst for the stock.
Merger And Pipeline ExpansionThe merger with Wex Pharmaceuticals introduces Halneuron, a promising non-opioid painkiller that has shown positive results in clinical trials, to the company's product pipeline.
Bears Say
Capital And OwnershipVirios shareholders are expected to account for approximately 6% of the new entity, suggesting a significant dilution of ownership.
Financial PerformanceVirios reported no revenues and a net loss of $0.05 per share in the quarter, reflecting financial challenges.
Research And DevelopmentThe company may not have the resources to independently conduct a large late-stage study to support approval, and may need to seek a partner to co-develop IMC-2.
---
Ownership Overview
62.99%
Insiders
15.68% Mutual Funds
― Other Institutional Investors
5.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $2.50 and its highest was $26.00 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Currently, no data Available
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Nov 11, 2024 which is in 3 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Aug 08, 2024. The company reported -$1.25 earnings per share for the quarter, beating the consensus estimate of -$1.583 by $0.333.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -$1.25.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 1,332,268 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$1.25 in its last earnings report, beating expectations of -$1.583. Following the earnings report the stock price went down -4.274%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
---
Dogwood Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.73%
12-Months-Change
Fundamentals
Return on Equity
-119.56%
Trailing 12-Months
Asset Growth
-30.24%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia.
---
DWTX Earnings Call
Q1 2024
0:00 / 0:00
---
DWTX Stock 12 Month Forecast
Average Price Target
$15.00
▲(237.08% Upside)
Technical Analysis
Best Analysts Covering DWTX
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-17.63%
reiterated a buy rating 14 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -17.63% per trade.
---